Table S1 - Diagnostic performances and therapeutic impact of the Unyvero Implant and Tissue Infection multiplex PCR in periprosthetic joint infections

<strong>Aim: </strong>We evaluated the diagnostic performances of Unyvero Implant and Tissue Infection multiplex PCR (mPCR) (Curetis) and the clinical impact of this PCR on therapeutic decisions. <strong>Materials &amp; methods:</strong>AmPCR was performed on 33 joint fluids in addition to standard culture. A group of experts analyzed <em>a posteriori </em>the impact of the mPCR in the patient management. <strong>Results: </strong>The rate of concordance with culture was 74% (20<strong>/</strong>27). The sensitivity of the PCR was 59% and the specificity 90%. Clinicians would have started an appropriate treatment sooner for six patients (from 2 to 22 days earlier). <strong>Conclusion: </strong>The PCR would improve the management of 22% of the patients. For other patients, mPCR results have to be completed with the culture.

研究目的：本研究评估了Curetis公司研发的Unyvero植入物与组织感染多重聚合酶链反应（multiplex PCR, mPCR）的诊断效能，以及该检测方法对临床治疗决策的影响。
材料与方法：本研究对33份关节液样本同步开展了AmPCR检测与标准微生物培养。专家组回溯性分析了该mPCR检测对患者诊疗管理的影响。
研究结果：该检测与标准培养法的符合率为74%（20/27）。mPCR检测的灵敏度为59%，特异度为90%。临床医师可提前为6例患者启动恰当的抗感染治疗（提前2至22天不等）。
研究结论：该mPCR检测可改善22%患者的诊疗管理流程。对于其余患者，需结合标准微生物培养结果对mPCR检测结果进行补充验证。